The authors of a recent editorial present a case for considering twice-weekly rather than the standard thrice-week hemodialysis, a shift that can reduce exposure to the COVID-19 coronavirus, conserve personal protective equipment and other benefits.
Patients on dialysis are at especially high risk of infection and experiencing severe complications of infection. The pandemic may prompt patients and their physicians to consider the benefits of dialyzing at home.
Patients with chronic kidney disease who have serum uromodulin levels above 55.6 ng/mL have decreases risks of end-stage kidney disease, major cardiovascular events, and death, a study found.
Patients on hemodialysis who received high-dose had similar rates of infection and rates of hospitalization for infection compared with those treated with low-dose IV iron, a secondary analysis of the PIVOTAL trial revealed.
Warfarin, a vitamin K antagonist, was associated with no benefits and a potential harm in patients with end-stage kidney disease and atrial fibrillation, a meta-analysis showed.
The National Kidney Foundation issued a statement today urging patients on dialysis to continue undergoing treatments during the COVID-19 pandemic. “It is extremely important for kidney patients to continue with their regularly scheduled dialysis treatments and take extra precautions when visiting the facilities to best protect their health,” said Joseph Vassalotti, MD, Chief Medical Officer for NKF. “Skipping…
In a study of kidney transplant recipients, mean hemoglobin levels rose from 10.69 g/dL prior to transplantation to 14.45 g/dL at 1 year after transplantation.
Women with hypertensive disorders of pregnancy not only appear to have elevated risks for cardiovascular and cerebrovascular disease, but also kidney disease.
Patients starting on peritoneal dialysis or in-center hemodialysis have similar mortality risks, according to a new systematic review and meta-analysis of studies using propensity score matching to compare mortality risks between the modalities.
The study expands on prior research by incorporating a larger more diverse CKD/ESRD population followed over a longer period, and it adjusted for several important confounders, such as kidney transplant status.
